Search Results

You are looking at 101 - 110 of 371 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, Asher Chanan-Khan, Steve E. Coutre, Randall S. Davis, Christopher D. Fletcher, Brian Hill, Brad S. Kahl, Manali Kamdar, Lawrence D. Kaplan, Nadia Khan, Thomas J. Kipps, Jeffrey Lancet, Shuo Ma, Sami Malek, Claudio Mosse, Mazyar Shadman, Tanya Siddiqi, Deborah Stephens, Nina Wagner, Andrew D. Zelenetz, Mary A. Dwyer, and Hema Sundar

study. The most common treatment-related toxicities were neutropenia (grade 3/4; 20%) and infections (any grade; 53%), including those requiring intravenous antibiotics (27%). In a study of 358 patients with untreated HCL, cladribine resulted in a CR

Full access

Emerging Therapies in the Treatment of Bladder Cancer

Presented by: Arlene O. Siefker-Radtke

govitecan may experience side effects. Neutropenia, including febrile neutropenia, and diarrhea, nausea, and vomiting were among the most frequently reported treatment-related adverse events in the study population. 10 “Patients with bladder cancer, in

Full access

Pertuzumab in the Treatment of HER2+ Breast Cancer

Komal Jhaveri and Francisco J. Esteva

neutropenia were noted in 2 of 2 patients treated with 75 mg/m 2 of docetaxel and 1050 mg of pertuzumab every 3 weeks. Of 5 patients, 2 who received 100 mg/m 2 of docetaxel and 420 mg of pertuzumab (after a loading dose of 840 mg) every 3 weeks experienced

Full access

Evolving Paradigms in the Treatment of Newly Diagnosed Multiple Myeloma

Alessandra Larocca and Antonio Palumbo

very good partial response (VGPR) were particularly higher with RD, as was 1-year PFS. However, this improvement did not translate into an overall survival advantage. The incidences of grade 3/4 neutropenia (21% vs. 5%) and thromboembolic events (24% vs

Full access

New NCCN Guidelines: Cancer Management in People Living With HIV

Gita Suneja

, vinblastine, and dacarbazine) is recommended for treating HL in people with HIV infection. However, dose reductions may be required for prolonged severe neutropenia. 7 In this population, growth factors may be required for those with a low CD4-positive T

Full access

Optimizing Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Presented by: Anthony Mato

differences in atrial fibrillation favoring zanubrutinib over ibrutinib (10.1% vs 2.5%), although neutropenia occurred more frequently in patients receiving zanubrutinib. Hypertension was the same with either agent. The ELEVATE-RR trial, which compared

Full access

Correspondence

Marc Fishman, William Shimp, James Krook, Akhil Kumar, and William J.M. Hrushesky

alternative choices but rather avoiding use of the drug with chemotherapy regimens with a low risk of febrile neutropenia. 2 , 3 We agree with Dr. Burstein that a serious dialogue on cost-effective care is needed. Talk, however, is clearly not enough. We

Full access

The Top Five in Oncology: Where Do We Go From Here?

Harold J. Burstein

. No white cell–stimulating factors for primary prevention of febrile neutropenia for patients with less than 20% risk for this complication. If the ancient adage, “First, do no harm” is still sacred, then the next line would be “Second, do no

Full access

New Meets Old: A Case Study and Review of Novel Therapeutics for the Treatment of CLL in Older Patients

Neel K. Gupta and Charalambos Andreadis

adverse events were neutropenia (≈33%) and infusion-related reactions (≈20%). The study 16 showed that obinutuzumab/chlorambucil induced deeper and longer remissions than rituximab/chlorambucil, and the FDA subsequently approved the combination of

Full access

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Shaji K. Kumar, Natalie S. Callander, Kehinde Adekola, Larry D. Anderson Jr, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Christopher D’Angelo, Srinivas Devarakonda, Noura Elsedawy, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Hans C. Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A. Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Rashmi Kumar, and Jenna Snedeker

neutropenia. 8 The open-label phase III APOLLO trial randomly assigned patients with relapsed/refractory disease and at least one previous line of therapy (n=304) to receive pomalidomide/dexamethasone or daratumumab/pomalidomide/dexamethasone. With a median